CN105748518B - Anti-apolexis composition comprising fat stem cell extract - Google Patents
Anti-apolexis composition comprising fat stem cell extract Download PDFInfo
- Publication number
- CN105748518B CN105748518B CN201610161141.0A CN201610161141A CN105748518B CN 105748518 B CN105748518 B CN 105748518B CN 201610161141 A CN201610161141 A CN 201610161141A CN 105748518 B CN105748518 B CN 105748518B
- Authority
- CN
- China
- Prior art keywords
- stem cell
- apolexis composition
- culture
- cell extract
- fat stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 41
- 239000000284 extract Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 238000000197 pyrolysis Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- -1 P-hydroxybenzoic acid Methyl esters Chemical class 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 101710168454 Beta-galactosidase A Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
OD590 | Concentration | H9C2 | PC12 | HDF |
Control group | - | 0.77±0.03 | 0.56±0.02 | 0.84±0.04 |
Model group | - | 0.52±0.02 | 0.31±0.01 | 0.61±0.03 |
Embodiment 1 | 10μg/L | 0.69±0.03 | 0.48±0.02 | 0.76±0.03 |
30μg/L | 0.78±0.03 | 0.54±0.03 | 0.83±0.04 | |
Comparative example 1 | 10μg/L | 0.58±0.02 | 0.37±0.01 | 0.68±0.02 |
30μg/L | 0.62±0.03 | 0.45±0.02 | 0.74±0.03 | |
Comparative example 2 | 10μg/L | 0.60±0.03 | 0.41±0.03 | 0.71±0.03 |
30μg/L | 0.67±0.03 | 0.47±0.03 | 0.78±0.02 |
Beta galactosidase | Concentration | H9C2 | PC12 | HDF |
Control group | - | 1764±87 | 892±42 | 1344±98 |
Model group | - | 7942±274 | 4672±148 | 6109±176 |
Embodiment 1 | 10μg/L | 2542±119 | 1614±94 | 1952±83 |
30μg/L | 1913±94 | 1035±75 | 1479±71 | |
Comparative example 1 | 10μg/L | 5274±189 | 3352±121 | 4743±194 |
30μg/L | 3751±157 | 2514±108 | 2719±164 | |
Comparative example 2 | 10μg/L | 4359±172 | 2845±147 | 3259±176 |
30μg/L | 3039±147 | 1861±113 | 2152±132 |
The death rate (%) | Average life span (day) | |
Control group | 51.3 | 127.5 |
Embodiment 1 | 5.2 | 269.6 |
Comparative example 1 | 21.9 | 184.3 |
Comparative example 2 | 14.3 | 224.9 |
Test example 1 | 1.3 | 292.6 |
Incubation period (s) | |
Control group | 61.9±6.7 |
Embodiment 1 | 30.9±4.8 |
Comparative example 1 | 49.5±4.2 |
Comparative example 2 | 40.3±3.9 |
Test example 1 | 25.2±4.4 |
OD value | |
Control group | 0.24±0.05 |
Embodiment 1 | 0.41±0.04 |
Comparative example 1 | 0.29±0.05 |
Comparative example 2 | 0.32±0.04 |
Test example 1 | 0.54±0.06 |
Index and spleen index (mg/g) | Thymus index (mg/g) | |
Control group | 3.9±0.7 | 1.7±0.3 |
Embodiment 1 | 5.7±1.1 | 2.8±0.5 |
Comparative example 1 | 4.4±0.6 | 1.9±0.4 |
Comparative example 2 | 4.8±0.5 | 2.2±0.4 |
Test example 1 | 6.1±1.2 | 3.2±0.6 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610161141.0A CN105748518B (en) | 2016-03-21 | 2016-03-21 | Anti-apolexis composition comprising fat stem cell extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610161141.0A CN105748518B (en) | 2016-03-21 | 2016-03-21 | Anti-apolexis composition comprising fat stem cell extract |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105748518A CN105748518A (en) | 2016-07-13 |
CN105748518B true CN105748518B (en) | 2019-06-07 |
Family
ID=56345394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610161141.0A Active CN105748518B (en) | 2016-03-21 | 2016-03-21 | Anti-apolexis composition comprising fat stem cell extract |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105748518B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11065188B2 (en) | 2019-05-29 | 2021-07-20 | Av Laboratories Llc | Applications and formulations of optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents |
CN114288202A (en) * | 2021-12-06 | 2022-04-08 | 广州沛妍医疗科技有限公司 | A sericin composition with antiaging effect, and its preparation method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101400787A (en) * | 2006-01-27 | 2009-04-01 | 株式会社Prostemics | Mass producing method of growth factor using adipose derived adult stem cells |
CN101652063A (en) * | 2007-02-06 | 2010-02-17 | T·J·杨 | Use gene therapy treatment and prevention neurodegenerative disease |
CN104224841A (en) * | 2014-09-13 | 2014-12-24 | 黑龙江天晴干细胞有限公司 | Method for preparing stem cell preparation |
CN104762260A (en) * | 2015-04-23 | 2015-07-08 | 广州赛莱拉干细胞科技股份有限公司 | Preparation method and application of adipose-derived mesenchymal stem cells and preparation thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120105948A (en) * | 2011-03-17 | 2012-09-26 | (주)프로스테믹스 | Enriched media of human adipose tissue-derived stem cells having regeneration effects of ectodermal origin cells and uses thereof |
-
2016
- 2016-03-21 CN CN201610161141.0A patent/CN105748518B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101400787A (en) * | 2006-01-27 | 2009-04-01 | 株式会社Prostemics | Mass producing method of growth factor using adipose derived adult stem cells |
CN101652063A (en) * | 2007-02-06 | 2010-02-17 | T·J·杨 | Use gene therapy treatment and prevention neurodegenerative disease |
CN104224841A (en) * | 2014-09-13 | 2014-12-24 | 黑龙江天晴干细胞有限公司 | Method for preparing stem cell preparation |
CN104762260A (en) * | 2015-04-23 | 2015-07-08 | 广州赛莱拉干细胞科技股份有限公司 | Preparation method and application of adipose-derived mesenchymal stem cells and preparation thereof |
Non-Patent Citations (3)
Title |
---|
Ultraviolet A Regulates the Stemness of Human Adipose Tissue-Derived Mesenchymal Stem Cells Through Downregulation of the HIF-1a via Activation of PGE2–cAMP Signaling;Jongsung Lee et al.;《Journal of Cellular Biochemistry》;20120702;第113卷;第3681-3691页 |
β-淀粉样蛋白对体外培养的神经干细胞作用研究;胥显民等;《中国病理生理杂志》;20051231;第21卷(第1期);第139-142页 |
脂肪来源干细胞相关生长因子及其作用的研究进展;赵珮娟等;《组织工程与重建外科杂志》;20131031;第9卷(第5期);第285-288页 |
Also Published As
Publication number | Publication date |
---|---|
CN105748518A (en) | 2016-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brini et al. | Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel | |
Wu et al. | Optimization of Glycyrrhiza polysaccharide liposome by response surface methodology and its immune activities | |
CN103327992B (en) | For prevent or treat inflammatory diseases comprise Caulis Trachelospermi extract and the pharmaceutical composition of Cortex Moutan extract and the method preparing this pharmaceutical composition | |
KR101742629B1 (en) | Cosmetic composition for promoting the stemness of adipose-derived stem cell containing apple stem cell extracts | |
De Siena et al. | Omentum-derived stromal cells improve myocardial regeneration in pig post-infarcted heart through a potent paracrine mechanism | |
Chen et al. | Timing of transplantation of autologous bone marrow derived mesenchymal stem cells for treating myocardial infarction | |
CN105748518B (en) | Anti-apolexis composition comprising fat stem cell extract | |
Ude et al. | Stromal vascular fraction for osteoarthritis of the knee regenerative engineering | |
JPWO2013136871A1 (en) | Persulfated chondroitin composition | |
Cong et al. | Current and novel therapeutics for articular cartilage repair and regeneration | |
KR101565856B1 (en) | Composition for promoting osteogenic differentiation of human mesenchymal stem cells comprising cortex mori radicis extract, patrinia saniculaefolia extract or mixture thereof | |
AU2018220880B2 (en) | Composition for cough | |
CN103040910A (en) | Cervus and cucumis polypeptide liposome injection | |
CN108904533A (en) | Dental pulp mescenchymal stem cell is preparing the purposes in cirrhosis treatment drug | |
CN109864964B (en) | Anti-aging composition containing stem cells and application thereof | |
CN107427546A (en) | Composition and its medicinal application containing interwined dragon conopsea extraction | |
CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
He et al. | Black phosphorus quantum dot-modified ADSCs as a novel therapeutic for periodontitis bone loss coupling of osteogenesis and osteoimmunomodulation | |
CN105030777B (en) | Enhancing ALK TKI curative effects, the compound and its preparation for delaying its resistance | |
CN104490802B (en) | Rhodioside enteric coatel tablets and preparation method thereof | |
US7387781B2 (en) | Agents for treating osteoporosis and inhibiting osteoclast formation | |
CN107468708A (en) | A kind of preparation method of Stem Cell Activity factor gel and the application in Hard agglut wound treatment | |
KR20120058864A (en) | Cosmetic composition for promoting the stemness of adipose-derived stem cell and proliferating skin cell containing bifidobacteria extracts | |
KR101529493B1 (en) | Perillae semen extracts for enhancing differentiation of osteoblast and inhibiting differentiation of osteoclast and use of thereof as bone formation promoting products and bone resorption inhibitory products | |
Park et al. | Trichostatin A enhances osteogenic differentiation through activation of ERK pathways in mouse bone marrow multipotent stromal cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160713 Assignee: ZHEN-AO GROUP Co.,Ltd. Assignor: DALIAN University Contract record no.: X2023210000229 Denomination of invention: Anti aging composition containing adipose stem cell extract Granted publication date: 20190607 License type: Common License Record date: 20231129 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160713 Assignee: Dalian Xinzerui Technology Co.,Ltd. Assignor: DALIAN University Contract record no.: X2023210000261 Denomination of invention: Anti aging composition containing adipose stem cell extract Granted publication date: 20190607 License type: Common License Record date: 20231130 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240208 Address after: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee after: Chengdu yishenrui Technology Co.,Ltd. Country or region after: China Address before: 116622 No. 10 Xuefu street, Jinzhou New District, Dalian, Liaoning. Patentee before: DALIAN University Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240223 Address after: Room 201, Unit 1, Building 5, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100000 Patentee after: Beijing Jiamei Kanglian Medical Technology Co.,Ltd. Country or region after: China Address before: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee before: Chengdu yishenrui Technology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |